MedTrace Logo

A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening

NCT07395479 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-13

No results posted yet for this study

Summary

This is a single-arm, open-label, single-center, dose-escalation Phase I platform study designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of an in vivo CAR-T therapy (V001 Injection, targeting BCMA, GPRC5D, DLL3,FcRH5, etc.) in patients with advanced malignant tumors.

Conditions

  • Advanced Malignant Tumours

Interventions

GENETIC

V001-BCMA

An in vivo CAR-T drug targeting BCMA administered intravenously

GENETIC

V001-GPRC5D

An in vivo CAR-T drug targeting GPRC5D administered intravenously

GENETIC

V001-DLL3

An in vivo CAR-T drug targeting DLL3 administered intravenously

GENETIC

V001-FcRH5

An in vivo CAR-T drug targeting FcRH5 administered intravenously

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Shuhang Wang, PhD · Clinical Trial Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-21
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07395479 on ClinicalTrials.gov